Next Article in Journal
Targeting the Metabolic Adaptation of Metastatic Cancer
Previous Article in Journal
Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
Previous Article in Special Issue
Fostering Prevention of Cervical Cancer by a Correct Diagnosis of Precursors: A Structured Case-Based Colposcopy Course in Finland, Norway and UK
Review

Urine HPV in the Context of Genital and Cervical Cancer Screening—An Update of Current Literature

1
Department of Obstetrics & Gynaecology, University Hospital of Larisa, 41334 Larisa, Greece
2
Department of Obstetrics & Gynaecology, University Hospital of Patras, 26504 Patras, Greece
3
Hellenic National Public Health Organization—ECDC, Marousi, 15123 Athens, Greece
*
Author to whom correspondence should be addressed.
Academic Editors: Raj Naik, Pierre Martin-Hirsch, Evangelos Paraskevaides, Maria Kyrgiou and Ruud L.M. Bekkers
Cancers 2021, 13(7), 1640; https://doi.org/10.3390/cancers13071640
Received: 7 February 2021 / Revised: 14 March 2021 / Accepted: 29 March 2021 / Published: 1 April 2021
(This article belongs to the Special Issue Prevention & Screening in Cervical Cancer)
Despite the substantial scientific evolution in cervical cancer prevention and related infrastructures, a plethora of women still miss the opportunity to detect their precancerous lesions at a curable stage by not participating in existing screening programs. Implementing sensitive screening modalities combined with easy sampling methods with minimal pain or discomfort such as self-sampling of vaginal and urine samples is increasingly applied. Self-sampling HPV modalities aimed to address this inequity, besides facilitating HPV genotyping as well as the measurement of related biomarkers in HPV-caused lesions and genital cancer. The low costs inflicted, the non-invasive nature, and the favorable acceptability profile of urine HPV detection give the potential to become a most promising tool that could expand the possibilities in changing genital and cervical cancer prevention strategies as well as in the surveillance and management of genital precancer.
Within the previous decades, following the widespread implementation of HPV-related biomarkers and computerization in liquid-based cytology, screening for lower genital tract malignancies has been optimized in several parts of the world. Many organized anogenital cancer prevention systems have reached a point at which efficacy is more a matter of population coverage and less of available infrastructures. Meanwhile, self-sampling modalities in which biologic material (vaginal secretions, urine, etc.) is obtained by the individual and not the clinician and subsequently undergoes examination for HPV biomarkers enjoy appreciating acceptance. Bygone the initial skepticism that vaginal or urine HPV represents “passenger” transient infections, extensive scientific work has been conducted to optimize high-risk HPV (hrHPV) detection from this “novel” biologic material. Nowadays, several state-of-the-art meta-analyses have illustrated that self-sampling techniques involving urine self-sampling represent a feasible alternative strategy with potentially enhanced population coverage possessing excellent performance and sensitivity. Recently published scientific work focusing on urine HPV was reviewed, and after a critical appraisal, the following points should be considered in the clinical application of hrHPV urine measurements; (i) use of first-void urine (FVU) and purpose-designed collection devices; (ii) using a preservation medium to avoid human/HPV DNA degradation during extraction and storage; (iii) using polymerase chain reaction (PCR) based assays, ideally with genotyping capabilities; (iv) processing of a sufficient volume of whole urine; and (v) the use of an analytically sensitive HPV test/recovery of cell-free HPV DNA in addition to cell-associated DNA. View Full-Text
Keywords: HPV; HPV urine; cervical cancer screening; HPV DNA; genotyping; mRNA E6 & E7; HPV methylation markers HPV; HPV urine; cervical cancer screening; HPV DNA; genotyping; mRNA E6 & E7; HPV methylation markers
MDPI and ACS Style

Daponte, A.; Michail, G.; Daponte, A.-I.; Daponte, N.; Valasoulis, G. Urine HPV in the Context of Genital and Cervical Cancer Screening—An Update of Current Literature. Cancers 2021, 13, 1640. https://doi.org/10.3390/cancers13071640

AMA Style

Daponte A, Michail G, Daponte A-I, Daponte N, Valasoulis G. Urine HPV in the Context of Genital and Cervical Cancer Screening—An Update of Current Literature. Cancers. 2021; 13(7):1640. https://doi.org/10.3390/cancers13071640

Chicago/Turabian Style

Daponte, Alexandros, George Michail, Athina-Ioanna Daponte, Nikoletta Daponte, and George Valasoulis. 2021. "Urine HPV in the Context of Genital and Cervical Cancer Screening—An Update of Current Literature" Cancers 13, no. 7: 1640. https://doi.org/10.3390/cancers13071640

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop